Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

Media Info

Our media releases, presentations for the media and useful links

Contact

Swiss Biotech Association
Stauffacherstrasse 16
8004 Zürich
T: +41 44 455 56 78
E-mail

2022

May 3, 2022

Swiss Biotech Report 2022 shows sector again performs exceptionally at all levels

Capital investments in Swiss biotech companies reached CHF 3.33B (USD 3.53B) with continuing strong international participation – R&D investments increased to a record-high CHF 2.56B (USD 2.71B) – The appetite for IPOs on the NASDAQ remains high and the new Sparks market of SIX Swiss Exchange for SMEs could offer an interesting alternative in the future – The number of employees in Swiss R&D biotech companies increased in 2021 by 9.5% – Public-Private Partnerships (PPPs) increasing in importance as drivers of innovation in existing and emerging areas – Similar to 2020, significant contributions to address the impact of the COVID pandemic were made by the Swiss biotech sector in 2021

February 14, 2022

Swiss Biotech Association welcomes referendum result on February 13, 2022

The industry association of the Swiss biotech start-ups and SMEs welcomes that the Swiss electorate has rejected the proposal to ban animal testing and clinical trials. This enables Switzerland to continue to play its leading international role in the development of innovative medicines and new medical therapies. Moreover, the Swiss healthcare system retains access to innovative medicines from abroad. With one of the strictest animal protection laws in the world, Switzerland also ensures that animal tests are carried out with the utmost care and will be replaced by alternative methods wherever possible.

January 17, 2022

Radical people’s initiative bans clinical trials and risks to severely damage the Swiss research hub and healthcare system

The Swiss Biotech Association emphasizes the serious consequences of the radical people’s initiative
«Yes to the ban on animal testing and clinical trials», which will be put to the vote on February 13, 2022. In addition to banning clinical trials in Switzerland, the initiative also calls for a ban on the import of new medicines developed using clinical trials. The adoption of this initiative would have a massive impact on the Swiss healthcare system and directly threatens Switzerland as a research location. Research-oriented companies and their academic research partners in universities and university hospitals would have to stop their research work or relocate significant parts of their research and development activities abroad.

Media releases & presentations 2022

Swiss Biotech Report 2022 shows sector again performs exceptionally at all levels

Download PDF of media release Download media presentation Capital investments in Swiss…

May 03, 2022
Swiss Biotech Report 2022: Die Branche entwickelt sich auf allen Ebenen hervorragend

Download PDF of media releaseDownload media presentation in English 2021 wurden 3,33…

May 03, 2022
Le Swiss Biotech Report 2022 montre que le secteur affiche à nouveau des performances exceptionnelles à tous les niveaux

Download PDF of media releaseDownload media presentation in English En 2021, CHF 3,33…

May 03, 2022
Presentation for the media: Swiss Biotech Report 2022

The Swiss Biotech Report media presentation 2022 is only available in English Download PDF

May 03, 2022
Swiss Biotech Association welcomes referendum result on February 13, 2022

Download PDF  The industry association of the Swiss biotech start-ups and SMEs…

Feb 14, 2022
Swiss Biotech Association begrüsst Abstimmungsresultat vom 13. Februar 2022

Download PDF Der Branchenverband der schweizerischen Biotech Startups und KMUs…

Feb 14, 2022
Swiss Biotech Association salue le résultat du vote sur le référendum du 13 février 2022

Download PDF L’association des start-up et PME suisses de biotechnologie salue…

Feb 14, 2022
Radical people’s initiative bans clinical trials and risks to severely damage the Swiss research hub and healthcare system

Download PDF  The Swiss Biotech Association emphasizes the serious consequences of the…

Jan 17, 2022

2021

September 7, 2021

Swiss Biotech Day: Switzerland is extraordinarily successful as a biotech hub and globally connected

Switzerland is one of the most attractive locations for biotech companies and benefits from a very high influx of venture capital. At the same time, Switzerland has excellent prerequisites for further expanding its strong position in manufacturing complex biopharmaceuticals, as illustrated by numerous reports, presentations and panel discussions at the leading Swiss biotech industry conference.

May 12, 2021

Weakening patent protection for COVID-19 vaccines does not help to accelerate vaccine production but endangers science-based innovation

The proposal to the WTO, to weaken the patent protection for COVID-19 vaccines, incorrectly portrays IP as the barrier to rapid access to vaccines. While this initiative does not address the crisis in an effective manner, it does send an extremely dangerous signal to innovators and investors alike. A robust and reliable IP protection is indispensable for science-based innovation. What sounds good at first glance is dangerous as it risks to significantly weaken our ability to foster and finance healthcare innovation.

April 20, 2021

Agility, leadership and innovation – New Swiss Biotech Report shows exceptional sector performance

Capital investments in Swiss biotech companies almost tripled from 2019 to 2020 reaching CHF 3.4B (USD 3.7B) – R&D investments increased by 10% to CHF 2.2B (USD 2.3B) – The number of employees in Swiss R&D biotech companies increased by 8% to 16,300 – High quality patent output helped maintain Switzerland’s top ranking in Global Innovation Index for the tenth consecutive year – From rapid diagnostic test and vaccine manufacturing to drug repurposing, Swiss biotech companies made significant contributions to address the impact of the COVID-19 pandemic

The Swiss Biotech Report “Aglity, leadership and innovation in the time of COVID-19” launched by the Swiss Biotech Association in conjunction with EY and eight other partner organizations provides analysis of funding, M&A activity and collaborations. The report also highlights projects and companies that were part of the Swiss response to the COVID-19 pandemic.

More on the Swiss Biotech Report

March 31, 2021

Swiss Biotech Association now at headquarters of the Basel Chamber of Commerce

The Swiss Biotech Association will open a representative office at the Basel Chamber of Commerce on April 1, 2021. This demonstrates its commitment to Basel as a life sciences location with its innovative companies. Together with the Basel Chamber of Commerce, they are committed to a strong, competitive life sciences industry in the Basel region and Switzerland.

February 26, 2021

Swiss Biotech Success Stories with new jury members

Since 2018, the Swiss Biotech Association has been honoring outstanding achievements with the Swiss Biotech Success Stories Awards. Innovative companies, entrepreneurs and scientists are recognized by the industry association for their significant successes and lasting contributions to the Swiss biotech industry. Stefanie Flückiger-Mangual, Seraina Gross and Daniela Marino have now joined the Swiss Biotech Success Stories jury.

More on the Swiss Biotech Success Stories

Media releases & presentations 2021

Swiss Biotech Day: Switzerland is extraordinarily successful as a biotech hub and globally connected

Download PDF Switzerland is one of the most attractive locations for biotech companies…

Sep 07, 2021
Swiss Biotech Day: Der Biotech-Standort Schweiz ist äusserst erfolgreich und weltweit vernetzt

Download PDF Die Schweiz gehört zu den attraktivsten Standorten für…

Sep 07, 2021
Swiss Biotech Day: En biotechnologie, la Suisse est extrêmement prospère et dispose d’un réseau mondial

Download PDF La Suisse figure parmi les sites les plus attrayants pour les entreprises…

Sep 07, 2021
Presentation for the media: Swiss Biotech Day 2021

The Swiss Biotech Report media presentation 2021 is only available in English Download PDF

Sep 07, 2021
Media release: Agility, leadership and innovation – New Swiss Biotech Report shows exceptional sector performance

Download PDF Capital investments in Swiss biotech companies almost tripled from 2019…

Apr 20, 2021
Medienmitteilung: Agilität, Führung und Innovation – Neuer Swiss Biotech Report zeigt hervorragende Branchenleistung

Download PDF Ob in der Entwicklung von Schnelldiagnosetests, neuer Therapiemethoden…

Apr 20, 2021
Presentation for the media: Swiss Biotech Report 2021

The Swiss Biotech Report media presentation 2021 is only available in English Download PDF

Apr 20, 2021
Swiss Biotech Association now at headquarters of the Basel Chamber of Commerce

Download PDF The Swiss Biotech Association will open a representative office at the…

Mar 31, 2021
Swiss Biotech Association neu am Sitz der Handelskammer beider Basel

Download PDF Die Swiss Biotech Association eröffnet am 1. April 2021 eine Repräsentanz…

Mar 31, 2021
Swiss Biotech Success Stories with new jury members

Download PDF Since 2018, the Swiss Biotech Association has been honoring outstanding…

Feb 26, 2021
Swiss Biotech Success Stories mit neuen Jurymitgliedern

Download PDF Seit 2018 zeichnet die Swiss Biotech Association hervorragende Leistungen…

Feb 26, 2021
Nouveaux membres du jury des Swiss Biotech Success Stories

Download PDF Depuis 2018, la Swiss Biotech Association distingue les performances…

Feb 26, 2021

2020

September 21, 2020

Seven outstanding Swiss biotech achievements awarded

Each year, the Swiss Biotech Association awards companies or individuals with the Swiss Biotech Success Stories Awards in recognition of outstanding achievements. Actelion, Debiopharm, Helsinn, Venture Kick, >>Venture>>, Venturelab, and the noble prize-winner Professor Werner Arber receive the awards in 2020.

More on the Swiss Biotech Success Stories

April 21, 2020

Swiss Biotech Report 2020 highlights continued sector growth

Over CHF 1 billion raised for private and public companies – Gene therapy, AI and advanced biologics manufacturing emerging as additional strengths – Licensing deals and collaborations boost revenues – Swiss biotech ecosystem becomes even more diverse
 
With one of the most comprehensive life sciences ecosystems in the world, Swiss biotech continues to thrive. The 2020 edition of the Swiss Biotech Report by the Swiss Biotech Association in conjunction with EY and seven other partners, provides highlights and analysis of funding, M&A and collaborations, as well as a special focus on the exciting new artificial intelligence scene.
 
 

April 21, 2020

Laureates nominated for the Swiss Biotech Success Story Awards

Each year, the Swiss Biotech Association awards companies or individuals in recognition of outstanding achievements.

The award winners for 2020 are Actelion, Debiopharm, Helsinn, Venture Kick, >>Venture>>, Venturelab, and the noble prize-winner Professor Werner Arber.

Nominated this year for the Swiss Biotech Success Stories Awards in 2021 are Bachem, Basilea, Esbatech, Lonza, and Novimmune.

More on the Swiss Biotech Success Stories

Media releases & presentations 2020

Media release: Seven outstanding Swiss biotech achievements awarded

Download PDF Each year, the Swiss Biotech Association awards companies or individuals…

Sep 21, 2020
Sieben herausragende Schweizer Biotech-Leistungen ausgezeichnet

Download PDF Die Swiss Biotech Association zeichnet jedes Jahr Unternehmen oder…

Sep 21, 2020
Sept avancées remarquables en biotechnologie suisse récompensées

Download PDF Chaque année, la Swiss Biotech Association décerne aux entreprises ou aux…

Sep 21, 2020
Media release: Swiss Biotech Report 2020 highlights continued sector growth

Download PDF Over CHF 1 billion raised for private and public companies Gene therapy,…

Apr 21, 2020
Medienmitteilung: Swiss Biotech Report 2020 – 1,2 Milliarden für Schweizer Biotech-Unternehmen

Download PDF 2019 wurden 1,2 Milliarden Franken in private und öffentliche…

Apr 21, 2020
Communiqué aux médias: Le Swiss Biotech Report 2020 souligne la poursuite de la croissance dans le secteur

Download PDF Plus d’un milliard de CHF ont été levés pour les entreprises…

Apr 21, 2020
Presentation for the media: Swiss Biotech Report 2020

The Swiss Biotech Report media presentation 2020 is only available in English Download PDF

Apr 21, 2020